GLP-1RA versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: An updated meta-analysis of randomized controlled trials
GLP-1RA reduce HF exacerbations and can play a role in reducing hospitalizations, improving patient's functional status, and significantly impacting the global healthcare burden of HF. However, the current data does not indicate any overall mortality benefit.
Authors
- Naveed Adoni
- Krishna Prasad Kurpad
- Bijeta Keisham (ORCID: https://orcid.org/0000-0003-1346-785X)
- Alina Brener
- Sanchit Duhan (ORCID: https://orcid.org/0000-0001-5071-3971)
- Anuj Garg (ORCID: https://orcid.org/0000-0003-0442-3863)
- Jurgen Shtembari
- Uday Kanakadandi
- Sanjay S. Mehta
Institutions
- Weifang Medical University (CN)
- Carle Foundation Hospital (US)
Publication Details
- Journal
- International Journal of Cardiology
- Published
- 2025-07-05
- DOI
- https://doi.org/10.1016/j.ijcard.2025.133604
- Citations
- 6
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 8.33